Open | 1.35 |
Previous Close | 1.44 |
Day Range | 1.21 - 1.70 |
52-Week Range | 1.21 - 130.39 |
All-Time High | 480,807.60 |
Avg. Volume (50-day) | 343,439.84 |
EPS (TTM) | -203.36 |
Next Earnings Date | - |
Last Earnings Date | - |
Forward Annual Dividend (Yield) | - |
Trailing Annual Dividend (Yield) | - |
Options | No |
P/E Ratio | -0.01 |
PEG Ratio | - |
Price to Book | 0.19 |
Price to Cash Flow | - |
Price to Free Cash Flow | - |
Total Sales (TTM) | - |
Revenue per Share (TTM) | - |
Shares Outstanding | 525.400 K |
Share Float (%) | 0.53 M |
% Held by Institutions | 2.51 |
Dividends Per Share (TTM) | - |
Ex-Dividend Date | - |
+/- EMA(20) | 4.81 (-68.61%) |
+/- SMA(50) | 7.32 (-79.37%) |
+/- SMA(200) | 12.9 (-88.29%) |
5-Day Perf. | -65.42% |
1-Month Perf. | -78.52% |
3-Month Perf. | -90.21% |
6-Month Perf. | -75.19% |
YTD Perf. | -89.28% |
1-Year Perf. | -98.72% |
RSI(14) | 21.55 |
ATR(14) | 1.48 |
ADX(14) | 16.71 |
Beta (5Y) | - |
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded by Vipin Kumar Chaturvedi in May 2009 and is headquartered in La Jolla, CA.
GRI has triggered the following predefined scans:
P&F Double Bottom Breakdown |
P&F Descending Triple Bottom Breakdown |
Elder Bar Turned Blue |
New 52-week Lows |
P&F Long Tail Down |
As a StockCharts Member, you can create your own unique alerts with the technical criteria that matters most to you. Stay ahead of important moves and never miss a thing in the markets.
As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere.